SCHEMBL29618548

SCHEMBL29618548

CCN(CCOC)c1ccc(N)nc1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
PSMD14 O00487 1/20 0.38
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
RECQL P46063 1/20 0.38
GFER P55789 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
NCF1 P14598 2/20 0.35
NOS3 P29474 1/20 0.35
NOS2 P35228 1/20 0.35
MTOR P42345 8/20 0.35
CRHR1 P34998 1/20 0.35
PIK3CA P42336 3/20 0.34
S100B P04271 1/20 0.33
AOC3 Q16853 1/20 0.33
HDAC6 Q9UBN7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24374911 1.00 ALDH1A1 (0.38) ALDH1A1L3MBTL1PSMD14CYP3A4TSHR
SCHEMBL6653846 0.83 ALDH1A1 (0.54) ALDH1A1L3MBTL1PSMD14CYP3A4TSHR
SCHEMBL13740899 0.83 CRHR1 (0.38) CRHR1
SCHEMBL2793198 0.81 BRAF (0.39) CYP3A4NCF1NOS3NOS2MTOR
SCHEMBL30585768 0.81 BRAF (0.39) CYP3A4NCF1NOS3NOS2MTOR
SCHEMBL23107378 0.79 HSD17B10 (0.36) ALDH1A1L3MBTL1PSMD14CYP3A4TSHR
SCHEMBL10580706 0.78 ALDH1A1 (0.64) ALDH1A1L3MBTL1PSMD14CYP3A4TSHR
SCHEMBL30116117 0.76 MAPT (0.38) ALDH1A1L3MBTL1MAPK1RECQL
SCHEMBL12927172 0.76 ALDH1A1 (0.41) ALDH1A1L3MBTL1PSMD14CYP3A4TSHR
SCHEMBL3822535 0.75 OXTR (0.43) ALDH1A1MTORPIK3CAHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12070457-B2 Substituted pyridines, pyridazines, pyrimidines, and 1,2,3-triazines as bruton's tyrosine kinase inhibitors HUTCHISON MEDIPHARMA LIMITED (CN) 2024-08-27 US disclosed
US-20230043030-A1 HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2023-02-09 US disclosed
US-20220125785-A1 HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2022-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220125785-A1 HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF CYP3A4, CYP4B1, CYP3A5 ALDH1A1 1919/4885L3MBTL1 4630/4885PSMD14 4368/4885
US-20230043030-A1 HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF CYP3A43, CYP3A5, CYP11B2 ALDH1A1 425/4885L3MBTL1 4863/4885PSMD14 4531/4885
US-12070457-B2 Substituted pyridines, pyridazines, pyrimidines, and 1,2,3-triazines as bruton's tyrosine kinase inhibitors ABL1, BTK, ABL2 ALDH1A1 3913/4885L3MBTL1 4115/4885PSMD14 3889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.